<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pilot Feasibility Stud</journal-id><journal-id journal-id-type="iso-abbrev">Pilot Feasibility Stud</journal-id><journal-title-group><journal-title>Pilot and Feasibility Studies</journal-title></journal-title-group><issn pub-type="epub">2055-5784</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27976752</article-id><article-id pub-id-type="pmc">5154043</article-id><article-id pub-id-type="publisher-id">95</article-id><article-id pub-id-type="doi">10.1186/s40814-016-0095-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Snee</surname><given-names>M. P.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>McParland</surname><given-names>L.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Collinson</surname><given-names>F.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lowe</surname><given-names>C. M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Striha</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Baldwin</surname><given-names>D. R.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Naidu</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sebag-Montefiore</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Gregory</surname><given-names>W. M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bestall</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hewison</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hinsley</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Franks</surname><given-names>K. N.</given-names></name><address><email>kevin.franks@nhs.net</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds, LS9 7TF UK </aff><aff id="Aff2"><label>2</label>Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, University of Leeds, 71-75 Clarendon Road, Leeds, LS2 9PH UK </aff><aff id="Aff3"><label>3</label>Respiratory Medicine Unit, David Evans Research Centre, Nottingham University Hospitals and University of Nottingham, Hucknall Rd, Nottingham, NG5 1PB UK </aff><aff id="Aff4"><label>4</label>School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, Edgbaston B15 2TT, UK </aff><aff id="Aff5"><label>5</label>Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, 101 Clarendon Rd, Leeds, LS2 9LJ UK </aff><aff id="Aff6"><label>6</label>Leeds Institute of Cancer and Pathology, Faculty of Medicine and Health, University of Leeds, Beckett Street, Leeds, LS9 7TF UK </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>2</volume><elocation-id>55</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><related-article related-article-type="corrected-article" id="d30e69" ext-link-type="doi" xlink:href="10.1186/s40814-016-0046-2"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum</title><p>After publication of the original article [<xref ref-type="bibr" rid="CR1">1</xref>], it came to the authors&#x02019; attention that a source of funding had been inadvertently omitted from the Acknowledgements section; support from Yorkshire Cancer Research should have mentioned originally.</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1186/s40814-016-0046-2.</p></fn></fn-group><ref-list id="Bib1"><title>Reference</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snee</surname><given-names>MP</given-names></name><name><surname>McParland</surname><given-names>L</given-names></name><name><surname>Collinson</surname><given-names>F</given-names></name><name><surname>Lowe</surname><given-names>CM</given-names></name><name><surname>Striha</surname><given-names>A</given-names></name><name><surname>Baldwin</surname><given-names>DR</given-names></name><etal/></person-group><article-title>The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection</article-title><source>Pilot Feasability Studies</source><year>2016</year><volume>2</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/s40814-016-0046-2</pub-id></element-citation></ref></ref-list></back></article>